GEHC Stock Forecast & Price Target

GE HealthCare Techs is attractive because 3Q'26 organic revenue growth of 6.2% more than doubled the low end of guidance, while adjusted EPS also beat consensus, reinforcing that demand and execution are improving across a diversified portfolio. PCS was the clearest proof point, with 8.8% organic growth versus expectations for a decline, and the company also raised FY26 organic growth to about 4.0%, EBIT margin to 15.5%-15.7%, EPS to $4.95-$5.05, and FCF to $1.6B+. Supportive backlog trends, improving orders, broad-based segment strength, and a recurring-revenue base that is roughly half of sales all point to a more durable growth profile into 2027.

GE HealthCare Techs is facing a weaker fundamental setup because its downside case assumes slower backlog conversion, softer demand for products like Photon Counting CT and Flyrcado, and a delayed shift toward recurring revenue even though about half of sales are recurring. Margin expansion also looks constrained, with tariffs and inflation cited as a ~170bps headwind to adjusted EBIT margin in 3Q26 and expected to remain similar in FY27, limiting gross margin improvement and operating leverage. Additional pressure from China stagnation, PCS underperformance, hospital capital spending uncertainty, and competitive and regulatory risks could hold revenue growth to low single digits and drive earnings deterioration.